Hello Psychedelic Investors! As I mentioned in the previous episode of the Psychedelic Investor, last week I had my first ever interview with the wonderful Sena who is interested in creating a resource for those new to investing in psychedelic stocks and investing in stocks in general.
For those interested in the basics on psychedelic investing, you can watch the entire video on:
The Medicine of Being Human :https://www.youtube.com/watch?v=p3d_t4GYG14&t=599s&ab_channel=TheMedicineofBeingHuman

#PsychedelicStocks #MindMed #ThePsychedelicInvestor

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Similar Posts

Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences

Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences

Interviews, Listen, Podcasts

In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. We discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain. 

BIG NEWS on MindMed’s Clinical Trials [ Important MMED/MMEDF UPDATES You Need to Know ]

BIG NEWS on MindMed’s Clinical Trials [ Important MMED/MMEDF UPDATES You Need to Know ]

Listen, Videos

Hello Psychedelic Investors! Today, we will focus on MindMed’s 2021 Investors Deck and Project Lucy & Project Layla’s clinical trials updates.
MindMed, ticker symbol MMED on the Canadian NEO Stock exchange, and MMEDF on the American OTC Market has updated their 2021 Investors Deck (TWICE) in this year. As a fellow MindMed geek, I did my due diligence to compare the information on both decks and there’s a few clinical trial changes and a few other updates I found important to discuss.

In this episode, we will discuss:

Timecodes
0:00 – Intro
3:02 – MindMed’s Project Lucy Updates
6:27 – MMED’s18-MC And Microdosing Updates
9:00 – LSD to treat Suicide Headaches
11:04 – Phase 1 Updates
14:06 – Stats Updates
15:32 – MindMed Stock Speculation Zone

Important to mention that after we shot this video, MindMed did answer our inquiry about the removed readout with “Hello – Sorry for the delay. We plan on filing the IND for Project Lucy in Q3 of 2021.”
I’m not sure if that means that there will be a readout in Q3 as well…

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video by Pressmaster from Pexels

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMEDF #MindmedStock

A Deep Dive Into MindMed’s Microdosing Program: Project Flow | Plus a NEW LSD Microdosing Study

A Deep Dive Into MindMed’s Microdosing Program: Project Flow | Plus a NEW LSD Microdosing Study

Learn, Videos

In today’s episode, we look at MindMed’s (Nasdaq: MNMD, NEO: MMED) Project Flow, which is their LSD microdosing division. At present, MindMed’s microdosing program is split into 2 projects: base testing of LSD microdoses in healthy individuals, and using LSD microdoses to treat adult ADHD.

We will explore the progress made on both fronts, and where the program will expand to in the future, such as psilocybin (magic mushrooms) microdosing.
Ultimately, MindMed wants to answer questions such as:

Can microdosing psychedelics treat ADHD?
Can microdosing LSD improve your concentration?
Can microdosing decrease your anxiety?
Does microdosing increase creativity?
Does microdosing improve your mood?

Recently MindMed announced they are ready to begin recruiting for a study testing the variations in effect when taking LSD microdoses in the morning, compared to at night. The study will also try to answer the last four above questions. We discuss this study extensively.

Links:
MindMed Project Flow: https://mindmed.co/psychedelic-inspired/#scroll_section-2
MindMed New study: https://psilocybinalpha.com/news/mindmed-launches-study-of-low-dose-lsd-effects-on-sleep-and-cognitive-measures

Imperial College of London study: https://www.theguardian.com/science/2021/mar/02/microdosing-lsd-benefits-might-be-placebo-effect-study-finds

Project Albert Quote: https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/

Kim Kuypers Study: https://www.nature.com/articles/s41598-021-01811-4

MindMed Investor’s Deck: https://mindmed.co/wp-content/uploads/2021/11/MindMed-Presentation-11.17-compressed.pdf

LSD for ADHD: https://mindmed.co/news/press-release/mindmed-advances-phase-2-lsd-microdosing-trial-for-adult-adhd-appoints-principal-investigator/
https://mindmed.co/news/press-release/mindmeds-microdosing-division-further-expands-phase-2-clinical-trial-of-microdosing-lsdfor-adult-adhd/

Previous MindMed LSD study: https://mindmed.co/news/press-release/mindmed-announces-the-completion-of-phase-1-study-measuring-dosing-effects-of-lsd/

Enjoy the episode!

Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Mindmed #MNMDstock #Microdosing

Interview with Trevor Millar, Advisor, NeonMind Biosciences

Interview with Trevor Millar, Advisor, NeonMind Biosciences

Interviews, Listen, Podcasts

In our conversation with Trevor, we have the opportunity to discuss some of the psychedelic-based treatments NeonMind is currently focused on developing to help tackle obesity. Obesity is one of the more prevalent health conditions today affecting millions of individuals worldwide. The World Health Organization has claimed that obesity has reached epidemic proportions globally with at least 2.8 million people dying each year as a result of being overweight or obese. 

Is investing in PSYCHEDELIC STOCKS the future🍄? (Intro to The Psychedelic Investor)

Is investing in PSYCHEDELIC STOCKS the future🍄? (Intro to The Psychedelic Investor)

Listen, Videos

So why do we think psychedelic stocks are the next big thing? Here is the story of how the Joe Rogan Podcast led one Tesla Investor to investing in psychedelic stocks and starting the channel: The Psychedelic Investor 🍄.

From MindMed (MMED/MMEDF) to Compass Pathways (CMPS) and other growth stocks in the psychedelic landscape, we aim to cover the developments in the psychedelic stocks field. Our main goal is creating a community where information can be shared and we can learn each other. So is investing in psychedelic stocks the future? Guess we’ll find out soon enough: together.

👍Like & Subscribe to join us on our journey to achieving Alpha Returns

Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#PsychedelicStocks #MindMed #JoeRogan #Tesla #ShroomStocks #MMED #CMPS #ThePsychedelicInvestor

Interview With Dr. Gorman

Interview With Dr. Gorman

Listen, Podcasts

In this episode of the Psychedelic Spotlight podcast, we speak with Dr. Ingmar Gorman who is the Co-Founder and Lead Trainer at Fluence, and a Principal Investigator for the Multidisciplinary Association for Psychedelic Studies (“MAPS”).ya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.